Celltech/Bayer Bay10-3356 to enter Phase III U.S. trials for septic shock in 1997.
Executive Summary
CELLTECH/BAYER BAY10-3356 TO ENTER PHASE III FOR SEPTIC SHOCK IN 1997 in the U.S. if pivotal trials of the companies' predecessor compound for septic shock, Bay-X1351, shows proof of principle, Celltech Group Chief Executive Peter Fellner, PhD, told a UBS Securities' life sciences conference in London April 16. Development of Bay10-3356 for septic shock will run about two years behind development of the murine Bay-X1351 for the indication, Fellner said. Bayer is conducting pivotal trials of Bay-X1351 ("The Pink Sheet" April 14, T&G-4).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth